IntravenousLocally advanced urothelial carcinoma, Metastatic urothelial carcinomaAdult: 1.2 g once every 3 weeks via infusion over 60 minutes, until disease progression or unacceptable toxicity. Dose modification, interruption, or discontinuation (based on severity) may be required if immune- or infusion-related reactions occur (refer to detailed product guideline).
IntravenousLocally advanced non-small cell lung carcinoma, Metastatic non-small cell lung carcinomaAdult: For previously treated: 1.2 g once every 3 weeks via infusion over 60 minutes, until disease progression or unacceptable toxicity. As first-line treatment: 1.2 g on day 1 every 3 weeks via infusion over 60 minutes followed by bevacizumab, paclitaxel, and carboplatin for 4-6 cycles of chemotherapy, until disease progression or unacceptable toxicity occurs. Dose modification, interruption, or discontinuation (based on severity) may be required if immune- or infusion-related reactions occur (refer to detailed product guideline).
|
Withdraw 20 mL and dilute in 250 mL NaCl 0.9% solution to prepare a final concentration 4.4 mg/mL. Mix gently. Do not shake.
|
|
|
Significant: Endocrine disorders (e.g. hyper/hypothyroidism, type 1 diabetes mellitus, adrenal insufficiency), hypophysitis, uveitis, iritis, other immune-mediated effects (e.g. meningoencephalitis, myasthenia gravis, Guillain-Barre syndrome), pancreatitis, myocarditis.
Blood and lymphatic system disorders: Thrombocytopenia, autoimmune hemolytic anaemia.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain, dysphagia.
General disorders and admin site conditions: Pyrexia, fatigue, asthenia, influenza-like illness.
Immune system disorders: Hypersensitivity.
Investigations: Increased AST and ALT.
Metabolism and nutrition disorders: Decreased appetite, hypokalaemia, hyponatremia.
Musculoskeletal and connective tissue disorders: Arthralgia, back pain, musculoskeletal pain, chills.
Respiratory, thoracic and mediastinal disorders: Cough, dyspnoea, hypoxia, nasal congestion, nasopharyngitis.
Skin and subcutaneous tissue disorders: Rash, pruritus.
Vascular disorders: Hypotension.
Potentially Fatal: Immune-related hepatitis, pneumonitis and interstitial lung disease, colitis or diarrhoea, severe infection (e.g. sepsis, herpes encephalitis), infusion-related reactions.
|
IV: Z (May cause immune-mediated foetal rejection. Generally not recommended unless clinically required. Consult product literature for specific recommendations.)
|
This drug may cause fatigue, if affected, do not drive or operate machinery.
|
Monitor PD-L1 expression status, LFT, thyroid function, serum glucose; signs/symptoms of colitis, diarrhoea, endocrinopathies, hepatitis, hypophysitis, infection, infusion reactions, pneumonitis, and ocular toxicity.
|
May enhance the adverse effect of belimumab.
|
Description:
Mechanism of Action: Atezolizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody which binds to programmed death ligand 1 (PD-L1) and selectively prevents the interaction between PD-1 and B7.1 (also known as CD80) receptors found on T-cells and antigen presenting cells, releasing PD-L1/PD-1 mediated inhibition of immune response thereby enhancing the immune response to tumour cells.
Pharmacokinetics:
Distribution: Volume of distribution at steady state: 6.9 L.
Excretion: Elimination half-life: 27 days.
|
Store between 2-8°C. Do not freeze. Protect from light.
This is a cytotoxic drug. Any unused portions should be disposed of in accordance with local requirements.
|
|
|
L01FF05 - atezolizumab ; Belongs to the class of PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors. Used in the treatment of cancer.
|
Anon. Atezolizumab. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 01/03/2019. Anon. Atezolizumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 01/03/2019. Buckingham R (ed). Atezolizumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 01/03/2019. Tecentriq (Genentech, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 01/03/2019.
|
Sign Out
